Abstract | BACKGROUND: METHODS: CP was induced in rats in vivo by dibutyltin dichloride (DBTC). Seven days after DBTC injection (day 7), a slow-release form of ONO-1301 (10 mg/kg; ONO-1301-treated group) or vehicle (DBTC-treated group) was injected. On days 14 and 28, we evaluated the histopathological CP score and mRNA expressions of HGF, cytokines, and collagen in the pancreas by real-time RT-PCR. In vitro, monocytes and pancreatic stellate cells (PSCs) were isolated from normal rat spleen and pancreas, respectively. The cytokine and collagen expressions of monocytes and PSCs were detected by real-time RT-PCR, and PSCs proliferation was examined by BrdU assay. RESULTS: Histopathological CP scores in vivo improved in the ONO-1301-treated group compared to the DBTC-treated group, particularly inflammatory cell infiltration on day 14 and interstitial fibrosis on day 28. HGF mRNA increased significantly after ONO-1301 administration, whereas IL-1β, TNF-α, TGF-β, MCP-1, and collagen mRNA decreased significantly. Cytokine expression in monocytes was suppressed in vitro not only by HGF, but also ONO-1301 alone. However, neither ONO-1301 nor HGF affected the proliferation, or cytokine or collagen expression of PSCs. CONCLUSIONS:
ONO-1301 suppresses pancreatic fibrosis in the DBTC-induced CP model by inhibiting monocyte activity not only with induction of HGF but also by ONO-1301 itself.
|
Authors | Yusuke Niina, Tetsuhide Ito, Takamasa Oono, Taichi Nakamura, Nao Fujimori, Hisato Igarashi, Yoshiki Sakai, Ryoichi Takayanagi |
Journal | Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
(Pancreatology)
2014 May-Jun
Vol. 14
Issue 3
Pg. 201-10
ISSN: 1424-3911 [Electronic] Switzerland |
PMID | 24854616
(Publication Type: Evaluation Study, Journal Article)
|
Copyright | Copyright © 2014 IAP and EPC. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Biomarkers
- Cytokines
- Delayed-Action Preparations
- Organotin Compounds
- Pyridines
- ONO 1301
- Hepatocyte Growth Factor
- Epoprostenol
- dibutyldichlorotin
|
Topics |
- Animals
- Biomarkers
(metabolism)
- Cytokines
(metabolism)
- Delayed-Action Preparations
- Epoprostenol
(agonists)
- Fibrosis
- Hepatocyte Growth Factor
(metabolism)
- Male
- Organotin Compounds
- Pancreas
(drug effects, metabolism, pathology)
- Pancreatitis, Chronic
(chemically induced, drug therapy, pathology)
- Pyridines
(pharmacology, therapeutic use)
- Random Allocation
- Rats
- Real-Time Polymerase Chain Reaction
- Reverse Transcriptase Polymerase Chain Reaction
- Treatment Outcome
|